Health and safety officials are keeping an eye on the situation south of the border, where federal health officials have temporarily halted the use of the Johnson & Johnson COVID-19 vaccine due to concerns about a small number of rare blood clotting events. The agency has also requested information from Janssen, the pharmaceutical company, on any cases of “rare blood clots.”
The company has also received the fourth one-of-a-kind shot of the “Johnson & Johnson” viral vaccine for use in the United States. Officials from the Department of Health and Human Services say they expect the same kind of push to get the vaccine in every part of the country.
They will also examine all available evidence to see if there are any similarities between the vaccine and a group of “extremely rare” bloodletting events, such as “jellyflowers” or “crisps.” In this year’s national health and safety campaign, the agency is also looking for the fourth shot of “the fourth unique vaccine.”
The World Health Organization said on Tuesday that it is awaiting the results of ongoing reviews of the Johnson & Johnson vaccine by American and European regulators. A clinical trial for the vaccine in children aged 12 to 17 has also been approved by Health Canada. The majority of adverse reactions reported during clinical trials were mild to moderate in severity and were resolved within a few days.